SLC5A2 and type 2 diabetes mellitus: A systematic review and meta-analysis of RCTs (randomized controlled trials) showed that SGLT2 inhibitors increased the total cholesterol, LDL-cholesterol, and HDL cholesterol, and decreased the TG levels in patients with T2DM [78].